Hvad angår det rejste spørgsmål om multiplicitet, anses det for hensigtsmæssigt at analysere undergrupperne statistisk, da dette har medvirket til at indsnævre indikationen til patienter med et gunstigere risk/ benefit - forhold for bicalutamid 150 mg.
As regards the multiplicity issue raised, it is considered appropriate to look at subgroups from a statistical viewpoint, as they have helped to narrow the indication to patients with a more favourable benefit/ risk balance for bicalutamide 150 mg.